Saving money in the European healthcare systems with biosimilars
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 3
Abstract
Introduction: The use of biotechnological manufactured drugs, or biologicals, has increased massively over the past few years. Used especially in the treatment of cancer and other severe diseases, biologicals incur high annual therapy costs and represent an additional burden for healthcare systems. Expenditure can be decreased by using cheaper biosimilars, produced following the patent expiration of the reference product. Here we present a model calculation that demonstrates the potential savings from using biosimilars for erythropoietins, granulocyte colony-stimulating factors, and monoclonal antibodies in EU national markets between 2007 and 2020. Methods: Using a sequential approach, we calculated the savings through the use of biosimilars for France, Germany, Italy, Poland, Romania, Spain, Sweden and UK. First, either a ‘top-down’ or a ‘bottom-up’ approach was chosen to forecast the expected quantity of consumed drugs. We then calculated average reimbursement prices using additional information about the healthcare systems in each country. Finally, we estimated the potential savings for the above molecule groups using developed country specific scenarios. Results: The use of biosimilars is expected to result in overall savings between Euros 11.8 billion and Euros 33.4 billion between 2007 and 2020, with largest savings expected for France, Germany and UK. Biosimilar monoclonal antibodies are expected to produce the greatest savings ranging from Euros 1.8 billion to Euros 20.4 billion. Biosimilar erythropoietins are expected to provide savings of between Euros 9.4 billion and Euros 11.2 billion, while granulocyte colony-stimulating factors could produce savings of between Euros 0.7 billion to Euros 1.8 billion. Conclusion: The increasing use of biosimilars is a valid option for decreasing healthcare expenditure on biological drugs.
Authors and Affiliations
Robert Haustein, Christoph de Millas, Ariane Höer, Bertram Häussler
Keywords
Related Articles
- EP ID EP355642
- DOI 10.5639/gabij.2012.0103-4.036
- Views 107
- Downloads 0
Pharmacokinetics of antimicrobials in obese children
Introduction: Childhood obesity is common and results in substantial morbidity. The most commonly prescribed drugs in obese children are antibiotics. However, physiological changes associated with childhood obesity can a...
Alleviating concerns around generic antiepileptic medications
Epilepsy features the unpredictable onset of seizures that can be devastating to a patient’s quality of life. Fortunately there are medications available to control the onset of seizures. But because these have to be tak...
Biosimilarity of anticancer monoclonal antibodies in the clinic
The European Medicines Agency recommends the use of pharmacodynamics (PD) markers when establishing biosimilarity, but no such biomarkers are known for the clinical efficacy of bevacizumab (Avastin). For this reason, con...
Biosimilarity in Latin America
The introduction of new legislation in Latin America for the approval of biosimilar products follows implementation of EU legislation in 2005 for biosimilars approval. The establishment of regulatory processes for these...
Do low- to middle-income countries need a biosimilar approval pathway based on a full comparability exercise?
Despite the fact that hepatitis C is a disease of global importance, many countries cannot afford the costly but effective combination treatment of peg-interferon and ribavirin, which was recently included in the World H...